Purolite and Repligen to commercially launch novel CH1 affinity resin
BioPharma Reporter
FEBRUARY 6, 2024
Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.
Let's personalize your content